On September 1, LEADS BIOLABS-B fell 5.05% in regular trading, trading at HK$68.55/share, with turnover of HK$143 million. The decline came after the company released its interim results on August 31, revealing widening losses that weighed on market sentiment.
For the six months ended June 30, LEADS BIOLABS-B reported revenue of RMB 35.969 million — its first revenue recognition after recording zero in the prior-year period — derived primarily from a one-time milestone payment and drug material supply under its LBL-047 out-licensing deal with Dianthus Therapeutics. However, net loss expanded 33.38% year-on-year to approximately RMB 222 million, while adjusted net loss widened 16% to RMB 171 million. R&D costs surged 44.9% to RMB 191 million, and administrative expenses rose 15.5% to RMB 41.4 million.
Despite positive catalysts — including a USD 10 million option exercise fee from Oblenio Bio for LBL-051 global rights received in August, and the NDA acceptance by China NMPA for its core product Opamtistomig targeting potential first-in-class 4-1BB therapy status — the persistent loss expansion pressured investor confidence.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments